YIPF3
Protein YIPF3
Also known as: C6orf109, dJ337H4.3, DKFZp566C243, FinGER3, KLIP1, YIPF3_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9GZM5
- Gene
- YIPF3
- Ensembl
- ENSG00000137207
- Chromosome
- 6
- Canonical length
- 350 aa
- Protein class
- Predicted intracellular proteins, Predicted membrane proteins, Transporters
- Subcellular location
- Nucleoplasm,Golgi apparatus
OverviewNCBI Gene
Predicted to be involved in cell differentiation. Located in Golgi apparatus and transport vesicle. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
350 residues, UniProt reviewed canonical sequence.
>Q9GZM5|YIPF3
1 MATTAAPAGG ARNGAGPEWG GFEENIQGGG SAVIDMENMD DTSGSSFEDM GELHQRLREE
61 EVDADAADAA AAEEEDGEFL GMKGFKGQLS RQVADQMWQA GKRQASRAFS LYANIDILRP
121 YFDVEPAQVR SRLLESMIPI KMVNFPQKIA GELYGPLMLV FTLVAILLHG MKTSDTIIRE
181 GTLMGTAIGT CFGYWLGVSS FIYFLAYLCN AQITMLQMLA LLGYGLFGHC IVLFITYNIH
241 LHALFYLFWL LVGGLSTLRM VAVLVSRTVG PTQRLLLCGT LAALHMLFLL YLHFAYHKVV
301 EGILDTLEGP NIPPIQRVPR DIPAMLPAAR LPTTVLNATA KAVAVTLQSHLocalizationUniProt · AlphaFold · HPA
Whether an antibody against YIPF3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 5
- Mean surface accessibility (rSASA)
- 0.44
- Highest tissue expression
- 146 nTPM
Expression across tissuesHPA
Tissue
- choroid plexus: 146 nTPM
- pancreas: 143 nTPM
- adrenal gland: 120 nTPM
- salivary gland: 116 nTPM
- stomach: 105 nTPM
- liver: 105 nTPM
Single-cell type
- esophageal apical cells: 342 nCPM
- syncytiotrophoblasts: 316 nCPM
- extravillous trophoblasts: 290 nCPM
- cytotrophoblasts: 225 nCPM
- migrating cytotrophoblasts: 184 nCPM
- epididymal principal cells: 145 nCPM
Immune cell
- neutrophil: 317 nTPM
- basophil: 148 nTPM
- eosinophil: 129 nTPM
- classical monocyte: 85 nTPM
- non-classical monocyte: 84 nTPM
- intermediate monocyte: 82 nTPM
Brain region
- choroid plexus: 117 nTPM
- thalamus: 73 nTPM
- pons: 73 nTPM
- medulla oblongata: 70 nTPM
- white matter: 69 nTPM
- hippocampal formation: 69 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.56
- gnomAD pLI
- 0.14
- gnomAD missense Z
- 0.62
- DepMap mean gene effect
- -0.13
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 8% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of YIPF3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads YIPF3 as an antibody target. Whether an autoantibody or antibody against YIPF3 could matter depends on whether native YIPF3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
YIPF3 is annotated at the cell surface, where native YIPF3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label YIPF3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...